Tata 1mg's core healthcare revenue rose 21% to ₹2,439.8 crore and net loss narrowed to ₹310 crore. The tech arm's profit fell sharply. The company is expanding diagnostics and B2B plans while preparing a $300 million fundraising round.
Alpha Score of 43 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Tata 1mg Healthcare Solutions Pvt. Ltd narrowed its net loss and grew revenue 21% in fiscal 2026, even as its technology arm posted a sharp drop in profit, according to the annual report of Tata Sons, the group’s investment holding company.
The core healthcare business reported a turnover of ₹2,439.8 crore for the year ended March 2026, up from ₹2,016.5 crore in FY25. The net loss shrank to ₹310 crore from ₹341.8 crore. The improvement came despite intense competition from Apollo 24|7, PharmEasy and Reliance Retail’s Netmeds, all of which are pushing deeper into diagnostics, teleconsultation and chronic care.
Tata 1mg Technologies Pvt. Ltd, the group’s tech services arm, posted a bigger revenue jump – up 32% to ₹496.1 crore – but profit after tax slumped to ₹17.5 crore from ₹65.4 crore. Tata Sons’ investment in the tech unit stood at ₹1,335 crore. The technology arm provides consultancy, technical support and agency services, and also handles some pharmaceutical sales, which makes its financials not directly comparable to the core healthcare business.
Tata Sons chairman N. Chandrasekaran described Tata 1mg as “India’s top-ranked e-pharma and e-diagnostics company” in his message to shareholders, placing it alongside Croma and BigBasket among Tata Digital’s key consumer businesses. Tata Digital itself reported a revenue of ₹35,990 crore in FY26, up from ₹32,188 crore, while its net loss widened to ₹4,974 crore from ₹4,610 crore, reflecting continued investment across its portfolio.
Tata 1mg is doubling down on business-to-business offerings, including healthcare plans for corporate clients, co-founder Gaurav Agarwal said in a 2025 interview. The company is also expanding its diagnostics lab centres beyond metro cities. Agarwal said the company is developing delivery workarounds to get medicines to customers within 30–60 minutes in major cities, bucking the quick-commerce trend.
Netmeds, the Reliance Retail unit, reported revenue of ₹44.7 crore in FY26, up marginally from ₹43.7 crore, with profit after tax slipping to ₹5.5 crore from ₹5.8 crore. Tata 1mg’s core healthcare business, however, is an order of magnitude larger, and the two companies are not directly comparable due to Netmeds’ focus on consultancy and agency services.
Tata 1mg raised $40 million through a rights issue from Tata Digital in September 2022. The company is preparing to raise $300 million in external capital, Agarwal said, though he declined to comment on the timeline. Tata Digital acquired a strategic stake in 1mg in 2021.
Tata Digital’s annual report highlighted Tata 1mg’s leadership in online pharmacy and diagnostics. The digital unit scaled to a gross merchandise value of ₹46,515 crore in FY26. The subsidiary financials underscore Tata 1mg’s growing importance within Tata Digital, which is being repositioned around financial services, loyalty and a portfolio of category-leading consumer businesses.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.